NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens | NIH: National Institute of Allergy and Infectious Diseases

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens | NIH: National Institute of Allergy and Infectious Diseases

Thursday, May 9, 2019 NIH Trial Evaluates Long-Acting HIV Medication for People Unable to Adhere to Strict Daily Regimens A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.